# The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study

> **NCT02227992** · PHASE3 · COMPLETED · sponsor: **Ethicon, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Hemorrhage
- Soft Tissue Bleeding
- Hepatic Parenchyma Bleeding

## Interventions

- **BIOLOGICAL:** EVARREST™ Sealant Matrix
- **DEVICE:** SURGICEL®

## Key facts

- **NCT ID:** NCT02227992
- **Lead sponsor:** Ethicon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-01
- **Primary completion:** 2021-10-27
- **Final completion:** 2021-11-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227992, "The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02227992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*